Drug intelligence / Profile preview

indomethacin + paracetamol

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Indomethacin + paracetamol is a combination medication that pairs a nonsteroidal anti-inflammatory drug (NSAID) with an analgesic to provide enhanced pain relief with fewer side effects than high-dose indomethacin alone. This combination is particularly useful for treating inflammatory conditions like rheumatoid arthritis, where the low-dose indomethacin (50 mg) provides anti-inflammatory effects while paracetamol (4 g) contributes additional analgesic properties. Studies have shown that this combination can achieve similar analgesic effects to high-dose indomethacin (150 mg) but with reduced gastrointestinal and other adverse effects.

Other names: indomethacin + acetaminophen

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on indomethacin + paracetamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on indomethacin + paracetamol.

Explore the full profile